The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Open accessAbstract
Background.: Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer that is rarely curable by surgery and is rapidly increasing in incidence. Relapsed ICC has a poor prognosis, and current systemic nontargeted therapies are commonly extrapolated from those used in other gastrointestinal malignancies. We hypothesized that genomic profiling of clinical ICC samples would identify genomic alterations that are linked to targeted therapies and that could facilitate a personalized approach to therapy. Methods.: DNA sequencing of hybridization-captured libraries was performed for 3,320 exons of 182 cancer-related genes and 36 introns of 14 genes frequently rearranged in cancer. Sample DNA was isolated from 40 μm of 28 formalin-fixed paraffin-embedded ICC specimens and sequenced to high coverage. Results.: The most commonly observed alterations were within ARID1A (36%), IDH1/2 (36%), and TP53 (36%) as well as amplification of MCL1 (21%). Twenty cases (71%) harbored at least one potentially actionable alteration, including FGFR2 (14%), KRAS (11%), PTEN (11%), CDKN2A (7%), CDK6 (7%), ERBB3 (7%), MET (7%), NRAS (7%), BRCA1 (4%), BRCA2 (4%), NF1 (4%), PIK3CA (4%), PTCH1 (4%), and TSC1 (4%). Four (14%) of the ICC cases featured novel gene fusions involving the tyrosine kinases FGFR2 and NTRK1 (FGFR2-KIAA1598, FGFR2-BICC1, FGFR2-TACC3, and RABGAP1L-NTRK1). Conclusion.: Two thirds of patients in this study harbored genomic alterations that are associated with targeted therapies and that have the potential to personalize therapy selection for to individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
PTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Sole, M., Tovar, V., Alsinet, C., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.001 · Cited by 575
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Guan, B., Wang, T.-L., & Shih, I.-M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1562 · Cited by 442
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.489 · Cited by 416
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Kobayashi, M., Ikeda, K., Saitoh, S., Suzuki, F., Tsubota, A., Suzuki, Y., Arase, Y., Murashima, N., Chayama, K., & Kumada, H. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2471::aid-cncr7>3.0.co;2-t · Cited by 247
KrasG12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma
O'Dell, M. R., Li Huang, J., Whitney-Miller, C. L., Deshpande, V., Rothberg, P., Grose, V., Rossi, R. M., Zhu, A. X., Land, H., Bardeesy, N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3596 · Cited by 192
Rearrangements of NTRK1 gene in papillary thyroid carcinoma
Greco, A., Miranda, C., & Pierotti, M. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.009 · Cited by 190
FGFR2 gene amplification and clinicopathological features in gastric cancer
Matsumoto, K., Arao, T., Hamaguchi, T., Shimada, Y., Kato, K., Oda, I., Taniguchi, H., Koizumi, F., Yanagihara, K., Sasaki, H., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.603 · Cited by 188
Intrahepatic Cholangiocarcinoma: New Insights in Pathology
Sempoux, C., Jibara, G., Ward, S., Fan, C., Qin, L., Roayaie, S., Fiel, M. I., Schwartz, M., & Thung, S. (2011) · Seminars in Liver Disease · doi:10.1055/s-0031-1272839 · Cited by 186
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2 -Amplified Gastric Cancer Cells
Chen, C.-T., Kim, H., Liska, D., Gao, S., Christensen, J. G., & Weiser, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0754 · Cited by 178
Genetics of Hepatobiliary Carcinogenesis
Nault, J., & Zucman‐Rossi, J. (2011) · Seminars in Liver Disease · doi:10.1055/s-0031-1276646 · Cited by 167
Nakano, H., Yamamoto, F., Neville, C., Evans, D., Mizuno, T., & Perucho, M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.1.71 · Cited by 133
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
Miyamoto, M., Ojima, H., Iwasaki, M., Shimizu, H., Kokubu, A., Hiraoka, N., Kosuge, T., Yoshikawa, D., Kono, T., Furukawa, H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.199 · Cited by 129
Intrahepatic Cholangiocarcinoma
Poultsides, G. A., Zhu, A. X., Choti, M. A., & Pawlik, T. M. (2010) · Surgical Clinics of North America · doi:10.1016/j.suc.2010.04.011 · Cited by 117
Jin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112
Genetic profiling of intrahepatic cholangiocarcinoma
Andersen, J. B., & Thorgeirsson, S. S. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283523c7e · Cited by 104
Lowery, W. J., Schildkraut, J. M., Akushevich, L., Bentley, R. C., Marks, J. R., Huntsman, D. D., & Berchuck, A. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318231f140 · Cited by 103
MET Signaling Pathway: A Rational Target for Cancer Therapy
Appleman, L. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7929 · Cited by 99
Bettayeb, K., Baunbæk, D., Delehouzé, C., Loaëc, N., Hole, A. J., Baumli, S., Endicott, J., Douc‐Rasy, S., Bénard, J., Oumata, N., et al. (2010) · Genes & Cancer · doi:10.1177/1947601910369817 · Cited by 92
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 84
Zhu, A. X. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.014 · Cited by 82
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients
Xu, R., Sun, J. P., Zhang, S. R., Zhu, G. S., Li, L. B., Liao, Y. L., Xie, J. M., & Liao, W. J. (2010) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2010.06.009 · Cited by 63
Lee, D., Do, I., Choi, K., Sung, C. O., Jang, K., Choi, D.-W., Heo, J. S., Choi, S. H., Kim, J., Park, J. Y., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.133 · Cited by 62
Schönleben, F., Qiu, W., Allendorf, J., Chabot, J. A., Remotti, H. E., & Su, G. H. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0917-4 · Cited by 59
DeHaan, R. D., Kipp, B. R., Smyrk, T. C., Abraham, S. C., Roberts, L. R., & Halling, K. C. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.09.004 · Cited by 58
Neuroblastoma: The impact of biology and cooperation leading to personalized treatments
Owens, C., & Irwin, M. S. (2012) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2012.683483 · Cited by 48
TP53 Mutations and mdm2 Protein Overexpression in Cholangiocarcinomas
Torre, G. D., Pasquini, G., Pilotti, S., Alasio, L. M., Civelli, E. M., Cozzi, G., Milella, M., Salvetti, M., Pierotti, M. A., & Severini, A. (2000) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200003000-00007 · Cited by 30
Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics
Chen, C. P., & Haas-Kogan, D. A. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.76 · Cited by 8
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Self-citationBanales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,153
Metadata
- Authors
- Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., Yelensky, R., Lipson, D., Morosini, D., Hawryluk, M., Catenacci, D. V. T., Miller, V. A., Churi, C., Ali, S., & Stephens, P. J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-21
- Volume
- 19
- Issue
- 3
- Pages
- 235-242
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2141042450
- Cited by
- 454
- References
- 43
- FWCI
- 29.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.